SENSUS HEALTHCARE ($NASDAQ:SRTS) reported their financial results for the second quarter of FY2023, ending on June 30, 2023. In comparison to the same period the previous year, total revenue for this quarter was USD 4.5 million, a decrease of 62.5%. Net income was reported to be USD -0.38 million, compared to the 3.52 million from the year prior.
On Thursday, SENSUS HEALTHCARE reported their second-quarter earnings results for FY2023. The company’s stock opened at $2.8 and closed at $2.7, representing a 5.6% drop from the previous day’s closing price of $2.9. This marks a decrease from the company’s positive performance in the first quarter. The report also noted that SENSUS HEALTHCARE’s operating expenses increased by 3% due to higher marketing and promotional costs.
Additionally, the company reported an increase in their inventory costs, which had a negative impact on their bottom line. Despite the drop in their stock price, SENSUS HEALTHCARE remains a highly competitive player in the healthcare industry. With the company continuing to invest in new technologies and services, they are well-positioned to deliver innovative products and services to their customers. The company’s management team remains confident that the company can continue to grow its revenues and profitability in the years ahead. They have stated that they are continuously evaluating new opportunities to expand their footprint in the healthcare market, and are confident that they will be able to deliver strong results for shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sensus Healthcare. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sensus Healthcare. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sensus Healthcare. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sensus Healthcare are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Sensus Healthcare Intrinsic Value Calculation
At GoodWhale, we provide investors with the data and tools to analyze the financials of SENSUS HEALTHCARE. Our proprietary Valuation Line shows that the fair value of SENSUS HEALTHCARE share is around $6.8. Currently, the SENSUS HEALTHCARE stock is traded at $2.7, which is 60.4% lower than its fair value. This suggests that now may be an opportune time for investors to purchase SENSUS HEALTHCARE shares. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products include radiation therapy systems and products for treating cancer with lasers. The company’s products are used by hospitals, clinics, and physicians. The company has a wide range of products and services, and it offers a variety of options for cancer treatments. The company’s products are competitively priced, and the company offers a variety of financing options.
– Apollo Endosurgery Inc ($NASDAQ:APEN)
Apollo Endosurgery Inc is a medical device company that focuses on developing less invasive surgical treatments. As of 2022, the company has a market capitalization of 271.04 million and a return on equity of -42.15%. The company’s products are used in a variety of procedures, including gastrointestinal, bariatric, and thoracic surgery. Apollo Endosurgery Inc has a strong research and development team that is constantly working to improve existing products and develop new ones. The company’s products are sold in over 60 countries around the world.
– InfuSystems Holdings Inc ($NYSEAM:INFU)
InfuSystems Holdings Inc is a company that provides infusion pumps and related services to the healthcare industry. The company has a market cap of 177.64M as of 2022 and a Return on Equity of 2.81%. The company’s products are used in the treatment of cancer, pain management, and other chronic conditions. The company’s products are sold through a network of distributors and dealers in the United States and Canada.
Bone Biologics Corp is a biotechnology company that focuses on the development of novel therapeutics for the treatment of bone diseases. The company’s market cap is 3.99M as of 2022. Its ROE is -16.65%. The company’s products are designed to improve the quality of life for patients with bone diseases.
SENSUS HEALTHCARE reported their second quarter financials for FY2023, which saw a decrease in total revenue by 62.5% year-on-year, and a net loss of USD -0.38 million. The market responded with a drop in stock price on the day. As such, investors considering SENSUS HEALTHCARE should conduct thorough research before investing, including analyzing the company’s financials, performance track-record, and competitive landscape. It is important to weigh the potential risks against anticipated rewards, and to understand the short-term and long-term implications of each decision.